Jamie Dananberg

CIK: 0001734424

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ANNX

Annexon, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

ANNX
Annexon, Inc.
Mar 2, 2026
Sale(S)
Direct
5.8K shares at avg. $5.43$32K
ANNX
Annexon, Inc.
Feb 19, 2026
Award(A)
Direct
56.3K shares-
ANNX
Annexon, Inc.
Feb 18, 2026
Sale(S)
Direct
5.3K shares at avg. $5.10$27K
ANNX
Annexon, Inc.
Feb 27, 2025
Award(A)
Stock Option (Right to Buy)
Direct
228.2K shares-
ANNX
Annexon, Inc.
Feb 18, 2025
Sale(S)
Direct
5.5K shares at avg. $2.96$16K
ANNX
Annexon, Inc.
Feb 27, 2024
Award(A)
Direct
45K shares-

		Type	Shares	Price		Ownership
Mar 2, 2026	ANNX Annexon, Inc.	Sale(S)	5,820	$5.43	$31,603	Direct
Feb 19, 2026	ANNX Annexon, Inc.	Award(A)	56,250	-	$0	Direct
Feb 18, 2026	ANNX Annexon, Inc.	Sale(S)	5,290	$5.10	$26,979	Direct
Feb 27, 2025	ANNX Annexon, Inc.	Award(A) Stock Option (Right to Buy)	228,225	-	-	Direct
Feb 18, 2025	ANNX Annexon, Inc.	Sale(S)	5,521	$2.96	$16,342	Direct
Feb 27, 2024	ANNX Annexon, Inc.	Award(A)	44,963	-	-	Direct

1-6 of 6 transactions

About Dananberg Jamie

Dananberg Jamie (SEC CIK 0001734424) files insider reports with the SEC as CHIEF MEDICAL OFFICER of Annexon, Inc. (ANNX).

Signal8 holds 5 ownership filings by Dananberg Jamie, all Form 4s, filed between Feb 20, 2025 and Mar 4, 2026. Those filings report 6 transactions, from Feb 27, 2024 to Mar 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Dananberg Jamie's filings is in BRISBANE, CA.

Recent filings by Dananberg Jamie

Mar 2, 2026: Open-market sale of ANNX shares (Form 4, code S).
Feb 19, 2026: Grant or award of ANNX shares (Form 4, code A).
Feb 18, 2026: Open-market sale of ANNX shares (Form 4, code S).
Feb 27, 2025: Grant or award of ANNX derivative securities (Form 4, code A).
Feb 18, 2025: Open-market sale of ANNX shares (Form 4, code S).

Other insiders filing for Annexon, Inc. (ANNX)

Love Douglas, PRESIDENT AND CEO
Blumenkranz Mark S., Director
Waddill William D., Director
Satter Muneer A, Director
JONES WILLIAM A JR, Director
Cockroft Bettina M., Director

How to read Form 4 transaction codes